Screener
Enliven Therapeutics ELVN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Total assets | $464,852 | $476,168 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,640 | $2,159 |
| Accrued expenses and other current liabilities | 9,847 | 14,409 |
| Total current liabilities | 11,487 | 16,568 |
| Total liabilities | 11,487 | 16,568 |
| Commitments and contingencies (Note 8) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's accounts payable?
- Enliven Therapeutics (ELVN) reported accounts payable of $1.64M in Q1 2026.
- How has Enliven Therapeutics's accounts payable changed year-over-year?
- Enliven Therapeutics's accounts payable increased by 5.0% year-over-year, from $1.56M to $1.64M.
- What is the long-term trend for Enliven Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Enliven Therapeutics's accounts payable has grown at a -8.0% compound annual growth rate (CAGR), from $10.46M to $7.5M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Enliven Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude